Myocardial perfusion in cardiac amyloidosis
- PMID: 38247182
- DOI: 10.1002/ejhf.3137
Myocardial perfusion in cardiac amyloidosis
Abstract
Aims: Cardiac involvement is the main driver of clinical outcomes in systemic amyloidosis and preliminary studies support the hypothesis that myocardial ischaemia contributes to cellular damage. The aims of this study were to assess the presence and mechanisms of myocardial ischaemia using cardiovascular magnetic resonance (CMR) with multiparametric mapping and histopathological assessment.
Methods and results: Ninety-three patients with cardiac amyloidosis (CA) (light-chain amyloidosis n = 42, transthyretin amyloidosis n = 51) and 97 without CA (three-vessel coronary disease [3VD] n = 47, unobstructed coronary arteries n = 26, healthy volunteers [HV] n = 24) underwent quantitative stress perfusion CMR with myocardial blood flow (MBF) mapping. Twenty-four myocardial biopsies and three explanted hearts with CA were analysed histopathologically. Stress MBF was severely reduced in patients with CA with lower values than patients with 3VD, unobstructed coronary arteries and HV (CA: 1.04 ± 0.51 ml/min/g, 3VD: 1.35 ± 0.50 ml/min/g, unobstructed coronary arteries: 2.92 ± 0.52 ml/min/g, HV: 2.91 ± 0.73 ml/min/g; CA vs. 3VD p = 0.011, CA vs. unobstructed coronary arteries p < 0.001, CA vs. HV p < 0.001). Myocardial perfusion abnormalities correlated with amyloid burden, systolic and diastolic function, structural parameters and blood biomarkers (p < 0.05). Biopsies demonstrated abnormal vascular endothelial growth factor staining in cardiomyocytes and endothelial cells, which may be related to hypoxia conditions. Amyloid infiltration in intramural arteries was associated with severe lumen reduction and severe reduction in capillary density.
Conclusion: Cardiac amyloidosis is associated with severe inducible myocardial ischaemia demonstrable by histology and CMR stress perfusion mapping. Histological evaluation indicates a complex pathophysiology, where in addition to systolic and diastolic dysfunction, amyloid infiltration of the epicardial arteries and disruption and rarefaction of the capillaries play a role in contributing to myocardial ischaemia.
Keywords: Amyloidosis; Extracellular volume; Infiltration; Ischaemia; Magnetic resonance imaging; Perfusion.
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Similar articles
-
Diagnostic value of the novel CMR parameter "myocardial transit-time" (MyoTT) for the assessment of microvascular changes in cardiac amyloidosis and hypertrophic cardiomyopathy.Clin Res Cardiol. 2021 Jan;110(1):136-145. doi: 10.1007/s00392-020-01661-6. Epub 2020 May 5. Clin Res Cardiol. 2021. PMID: 32372287 Free PMC article.
-
Myocardial Amyloidosis: The Exemplar Interstitial Disease.JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 2):2345-2356. doi: 10.1016/j.jcmg.2019.06.023. Epub 2019 Aug 14. JACC Cardiovasc Imaging. 2019. PMID: 31422120 Review.
-
Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.JACC Cardiovasc Imaging. 2019 May;12(5):823-833. doi: 10.1016/j.jcmg.2018.02.016. Epub 2018 Apr 18. JACC Cardiovasc Imaging. 2019. PMID: 29680336
-
Cardiac Amyloidosis: Diagnosis and Treatment Strategies.Curr Oncol Rep. 2017 Jul;19(7):46. doi: 10.1007/s11912-017-0607-4. Curr Oncol Rep. 2017. PMID: 28528458 Review.
-
Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3T cardiovascular magnetic resonance.J Cardiovasc Magn Reson. 2016 Apr 6;18:16. doi: 10.1186/s12968-016-0240-7. J Cardiovasc Magn Reson. 2016. PMID: 27048459 Free PMC article.
References
-
- Fontana M, Banypersad SM, Treibel TA, Abdel‐Gadir A, Maestrini V, Lane T, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light‐chain amyloidosis: A cardiac MR imaging study. Radiology 2015;277:388–397. https://doi.org/10.1148/radiol.2015141744
-
- Martinez‐Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond) 2018;18:s30–s35. https://doi.org/10.7861/clinmedicine.18‐2‐s30
-
- Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641–2654. https://doi.org/10.1016/S0140‐6736(15)01274‐X
-
- Chacko L, Martone R, Bandera F, Lane T, Martinez‐Naharro A, Boldrini M, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J 2020;41:1439–1447. https://doi.org/10.1093/eurheartj/ehz905
-
- Seward JB, Casaclang‐Verzosa G. Infiltrative cardiovascular diseases: Cardiomyopathies that look alike. J Am Coll Cardiol 2010;55:1769–1779. https://doi.org/10.1016/j.jacc.2009.12.040
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials